Pacira Cash And Short Term Investments vs Net Receivables Analysis

PCRX Stock

USD 30.33 0.13 0.43%

Pacira Pharmaceuticals financial indicator trend analysis is much more than just breaking down Pacira Pharmaceuticals prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Pacira Pharmaceuticals is a good investment. Please check the relationship between Pacira Pharmaceuticals Cash And Short Term Investments and its Net Receivables accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Pacira Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For more information on how to buy Pacira Stock please use our How to Invest in Pacira Pharmaceuticals guide.

Cash And Short Term Investments vs Net Receivables

Cash And Short Term Investments vs Net Receivables Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Pacira Pharmaceuticals Cash And Short Term Investments account and Net Receivables. At this time, the significance of the direction appears to have strong relationship.

The correlation between Pacira Pharmaceuticals' Cash And Short Term Investments and Net Receivables is 0.63. Overlapping area represents the amount of variation of Cash And Short Term Investments that can explain the historical movement of Net Receivables in the same time period over historical financial statements of Pacira Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of Pacira Pharmaceuticals' Cash And Short Term Investments and Net Receivables is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Cash And Short Term Investments of Pacira Pharmaceuticals are associated (or correlated) with its Net Receivables. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Net Receivables has no effect on the direction of Cash And Short Term Investments i.e., Pacira Pharmaceuticals' Cash And Short Term Investments and Net Receivables go up and down completely randomly.

Correlation Coefficient

0.63

Relationship Direction	Positive
Relationship Strength	Significant

View All Relationships

Cash And Short Term Investments

Short Term Investments is an account in the current assets section of Pacira Pharmaceuticals balance sheet. This account contains Pacira Pharmaceuticals investments that will expire within one year. These investments include stocks and bonds that can be liquidated by Pacira Pharmaceuticals fairly quickly. The sum of a company's cash on hand, including bank deposits and short-term, highly liquid investments that are easily convertible to known amounts of cash.

Net Receivables

Most indicators from Pacira Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Pacira Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Pacira Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For more information on how to buy Pacira Stock please use our How to Invest in Pacira Pharmaceuticals guide.At this time, Pacira Pharmaceuticals' Tax Provision is fairly stable compared to the past year. Sales General And Administrative To Revenue is likely to rise to 0.33 in 2024, whereas Selling General Administrative is likely to drop slightly above 63.1 M in 2024.

	2021	2022	2023	2024 (projected)
Interest Expense	31.8M	40.0M	23.8M	16.1M
Depreciation And Amortization	13.6M	61.4M	75.6M	79.4M

Interest Expense Depreciation And Amortization

Pacira Pharmaceuticals fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Long Term Debt	Cash And Short Term Investments	Net Receivables	Common Stock Total Equity	Common Stock Shares Outstanding	Short Term Investments	Non Current Liabilities Total	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross
Total Assets		0.79	0.68	0.96	0.8	0.92	0.22	0.95	0.32	0.58	0.65	0.98	0.84	0.56	0.97	0.78	0.96	0.61	0.65	0.36	0.98	0.94	0.72	0.84	0.92	0.92
Other Current Liab	0.79		0.69	0.68	0.87	0.8	-0.1	0.71	0.12	0.51	0.78	0.76	0.54	0.35	0.8	0.68	0.75	0.58	0.62	0.08	0.8	0.74	0.4	0.74	0.87	0.61
Total Current Liabilities	0.68	0.69		0.51	0.78	0.67	0.11	0.56	0.06	0.12	0.9	0.6	0.82	0.65	0.56	0.79	0.52	0.42	0.45	0.15	0.59	0.55	0.23	0.56	0.81	0.44
Total Stockholder Equity	0.96	0.68	0.51		0.66	0.87	0.22	0.91	0.38	0.6	0.48	0.96	0.76	0.47	0.93	0.66	0.98	0.6	0.66	0.39	0.93	0.96	0.8	0.81	0.79	0.98
Other Liab	0.8	0.87	0.78	0.66		0.77	-0.06	0.67	0.35	0.46	0.87	0.78	0.69	0.39	0.77	0.68	0.72	0.35	0.39	-0.07	0.79	0.69	0.43	0.61	0.88	0.62
Property Plant And Equipment Net	0.92	0.8	0.67	0.87	0.77		0.29	0.91	0.16	0.63	0.6	0.88	0.8	0.67	0.89	0.82	0.85	0.73	0.76	0.47	0.9	0.86	0.6	0.93	0.94	0.79
Current Deferred Revenue	0.22	-0.1	0.11	0.22	-0.06	0.29		0.28	-0.34	0.35	0.0	0.11	0.29	0.36	0.24	0.5	0.14	0.3	0.27	0.7	0.23	0.19	0.08	0.38	0.23	0.15
Net Debt	0.95	0.71	0.56	0.91	0.67	0.91	0.28		0.3	0.61	0.45	0.94	0.78	0.63	0.96	0.72	0.9	0.57	0.6	0.45	0.96	0.85	0.67	0.81	0.88	0.86
Retained Earnings	0.32	0.12	0.06	0.38	0.35	0.16	-0.34	0.3		0.04	0.08	0.46	0.34	0.16	0.29	-0.16	0.37	-0.34	-0.32	-0.42	0.31	0.25	0.4	-0.13	0.18	0.42
Accounts Payable	0.58	0.51	0.12	0.6	0.46	0.63	0.35	0.61	0.04		0.19	0.55	0.28	0.2	0.67	0.52	0.6	0.34	0.41	0.5	0.65	0.62	0.3	0.67	0.54	0.55
Cash	0.65	0.78	0.9	0.48	0.87	0.6	0.0	0.45	0.08	0.19		0.57	0.66	0.37	0.56	0.73	0.52	0.39	0.42	-0.05	0.59	0.55	0.29	0.52	0.78	0.43
Non Current Assets Total	0.98	0.76	0.6	0.96	0.78	0.88	0.11	0.94	0.46	0.55	0.57		0.78	0.5	0.96	0.65	0.98	0.53	0.58	0.23	0.97	0.93	0.76	0.76	0.87	0.94
Non Currrent Assets Other	0.84	0.54	0.82	0.76	0.69	0.8	0.29	0.78	0.34	0.28	0.66	0.78		0.81	0.72	0.8	0.71	0.44	0.46	0.39	0.75	0.69	0.55	0.65	0.83	0.72
Other Assets	0.56	0.35	0.65	0.47	0.39	0.67	0.36	0.63	0.16	0.2	0.37	0.5	0.81		0.48	0.68	0.38	0.34	0.34	0.56	0.51	0.39	0.22	0.53	0.66	0.35
Long Term Debt	0.97	0.8	0.56	0.93	0.77	0.89	0.24	0.96	0.29	0.67	0.56	0.96	0.72	0.48		0.74	0.94	0.58	0.61	0.34	1.0	0.89	0.71	0.82	0.9	0.88
Cash And Short Term Investments	0.78	0.68	0.79	0.66	0.68	0.82	0.5	0.72	-0.16	0.52	0.73	0.65	0.8	0.68	0.74		0.63	0.64	0.65	0.62	0.75	0.67	0.36	0.83	0.87	0.57
Net Receivables	0.96	0.75	0.52	0.98	0.72	0.85	0.14	0.9	0.37	0.6	0.52	0.98	0.71	0.38	0.94	0.63		0.59	0.66	0.28	0.95	0.97	0.78	0.79	0.81	0.97
Common Stock Total Equity	0.61	0.58	0.42	0.6	0.35	0.73	0.3	0.57	-0.34	0.34	0.39	0.53	0.44	0.34	0.58	0.64	0.59		0.98	0.55	0.57	0.65	0.5	0.88	0.61	0.56
Common Stock Shares Outstanding	0.65	0.62	0.45	0.66	0.39	0.76	0.27	0.6	-0.32	0.41	0.42	0.58	0.46	0.34	0.61	0.65	0.66	0.98		0.55	0.6	0.74	0.53	0.9	0.63	0.62
Short Term Investments	0.36	0.08	0.15	0.39	-0.07	0.47	0.7	0.45	-0.42	0.5	-0.05	0.23	0.39	0.56	0.34	0.62	0.28	0.55	0.55		0.33	0.35	0.15	0.63	0.32	0.3
Non Current Liabilities Total	0.98	0.8	0.59	0.93	0.79	0.9	0.23	0.96	0.31	0.65	0.59	0.97	0.75	0.51	1.0	0.75	0.95	0.57	0.6	0.33		0.9	0.71	0.82	0.91	0.89
Inventory	0.94	0.74	0.55	0.96	0.69	0.86	0.19	0.85	0.25	0.62	0.55	0.93	0.69	0.39	0.89	0.67	0.97	0.65	0.74	0.35	0.9		0.75	0.84	0.79	0.95
Other Current Assets	0.72	0.4	0.23	0.8	0.43	0.6	0.08	0.67	0.4	0.3	0.29	0.76	0.55	0.22	0.71	0.36	0.78	0.5	0.53	0.15	0.71	0.75		0.56	0.52	0.83
Other Stockholder Equity	0.84	0.74	0.56	0.81	0.61	0.93	0.38	0.81	-0.13	0.67	0.52	0.76	0.65	0.53	0.82	0.83	0.79	0.88	0.9	0.63	0.82	0.84	0.56		0.84	0.74
Total Liab	0.92	0.87	0.81	0.79	0.88	0.94	0.23	0.88	0.18	0.54	0.78	0.87	0.83	0.66	0.9	0.87	0.81	0.61	0.63	0.32	0.91	0.79	0.52	0.84		0.71
Property Plant And Equipment Gross	0.92	0.61	0.44	0.98	0.62	0.79	0.15	0.86	0.42	0.55	0.43	0.94	0.72	0.35	0.88	0.57	0.97	0.56	0.62	0.3	0.89	0.95	0.83	0.74	0.71

Click cells to compare fundamentals

Pacira Pharmaceuticals Account Relationship Matchups

Pacira Pharmaceuticals fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	831.1M	1.3B	2.1B	1.7B	1.6B	1.7B
Other Current Liab	18.2M	14.7M	117.9M	89.8M	64.2M	36.3M
Total Current Liabilities	107.7M	253.3M	521.1M	147.8M	97.4M	123.5M
Total Stockholder Equity	354.9M	619.7M	730.4M	775.0M	870.1M	913.6M
Other Liab	21.5M	17.4M	77.6M	37.8M	43.5M	24.9M
Property Plant And Equipment Net	142.8M	211.2M	264.8M	254.4M	234.9M	120.3M
Net Debt	273.7M	441.2M	543.3M	659.3M	432.7M	454.4M
Retained Earnings	(399.4M)	(253.9M)	(211.9M)	(148.8M)	(106.8M)	(112.1M)
Accounts Payable	12.8M	10.4M	10.5M	15.2M	15.7M	10.4M
Cash	78.2M	100.0M	585.6M	104.1M	153.3M	117.4M
Non Current Assets Total	422.5M	622.9M	1.2B	1.2B	1.1B	1.1B
Non Currrent Assets Other	11.0M	74.5M	76.4M	27.2M	36.0M	37.9M
Other Assets	971K	290.1M	153.4M	160.3M	1.0	0.95
Long Term Debt	306.0M	313.0M	674.5M	655.8M	513.8M	539.5M
Cash And Short Term Investments	292.0M	521.7M	656.4M	288.7M	278.6M	237.8M
Net Receivables	47.5M	53.0M	96.3M	98.4M	105.6M	110.8M
Common Stock Shares Outstanding	41.5M	43.7M	45.6M	46.5M	52.0M	35.9M
Short Term Investments	213.7M	421.7M	70.8M	184.5M	125.3M	137.9M
Liabilities And Stockholders Equity	831.1M	1.3B	2.1B	1.7B	1.6B	1.7B
Non Current Liabilities Total	368.4M	401.5M	823.8M	758.4M	606.9M	637.2M
Inventory	58.3M	64.7M	98.6M	96.1M	104.4M	109.6M
Other Current Assets	10.8M	12.3M	14.8M	15.2M	21.5M	22.6M
Other Stockholder Equity	754.0M	873.2M	942.1M	924.1M	976.6M	599.8M
Total Liab	476.1M	654.8M	1.3B	906.2M	704.3M	396.5M
Property Plant And Equipment Gross	142.8M	211.2M	264.8M	254.4M	370.3M	388.8M
Total Current Assets	408.6M	651.6M	866.0M	498.3M	510.0M	331.8M
Accumulated Other Comprehensive Income	322K	318K	167K	(380K)	247K	259.4K
Short Term Debt	4.9M	157.1M	382.6M	42.8M	17.4M	16.6M
Common Stock	42K	44K	45K	46K	52.9K	35.1K
Property Plant Equipment	104.7M	136.7M	264.8M	254.4M	292.5M	307.2M
Short Long Term Debt Total	351.9M	541.1M	1.1B	763.4M	586.0M	348.5M
Net Tangible Assets	151.0M	423.6M	(38.7M)	71.2M	81.9M	77.8M
Retained Earnings Total Equity	(388.2M)	(399.4M)	(253.9M)	(211.9M)	(190.7M)	(200.2M)
Long Term Debt Total	276.2M	290.6M	306.0M	313.0M	360.0M	240.7M
Capital Surpluse	709.7M	754.0M	873.2M	942.1M	1.1B	685.2M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

V	Visa Class A
BAC	Bank of America
GM	General Motors

When determining whether Pacira Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Pacira Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Pacira Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Pacira Pharmaceuticals Stock:

How To Invest In Pacira

Details

Is Pacira Stock a good investment?

Details

What is Pacira Pharmaceuticals' Net Worth?

Details

Largest Pharmaceuticals Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Pacira Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For more information on how to buy Pacira Stock please use our How to Invest in Pacira Pharmaceuticals guide.

You can also try the Aroon Oscillator module to analyze current equity momentum using Aroon Oscillator and other momentum ratios.

Complementary Tools for Pacira Stock analysis

When running Pacira Pharmaceuticals' price analysis, check to measure Pacira Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pacira Pharmaceuticals is operating at the current time. Most of Pacira Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Pacira Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pacira Pharmaceuticals' price. Additionally, you may evaluate how the addition of Pacira Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

	Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges
	USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA
	Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
	Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges
	Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets
	Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets
	Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings
	Economic Indicators Top statistical indicators that provide insights into how an economy is performing
	Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated
	Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments
	Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk

Is Pacira Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Pacira Pharmaceuticals. If investors know Pacira will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Pacira Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

0.291

Earnings Share

1.51

Revenue Per Share

14.706

Quarterly Revenue Growth

0.042

Return On Assets

0.0376

The market value of Pacira Pharmaceuticals is measured differently than its book value, which is the value of Pacira that is recorded on the company's balance sheet. Investors also form their own opinion of Pacira Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Pacira Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Pacira Pharmaceuticals' market value can be influenced by many factors that don't directly affect Pacira Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Pacira Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Pacira Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Pacira Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Pacira Cash And Short Term Investments vs Net Receivables Analysis

Cash And Short Term Investments vs Net Receivables

Cash And Short Term Investments vs Net Receivables Correlation Analysis

Correlation Coefficient

Cash And Short Term Investments

Net Receivables

Pacira Pharmaceuticals fundamental ratios Correlations

Pacira Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Pacira Pharmaceuticals fundamental ratios Accounts

Also Currently Popular

Complementary Tools for Pacira Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Non Current Liabilities Total	+ 1.0	Long Term Debt
Non Current Assets Total	+ 0.98	Total Assets
Non Current Liabilities Total	+ 0.98	Total Assets
Net Receivables	+ 0.98	Total Stockholder Equity
Property Plant And Equipment Gross	+ 0.98	Total Stockholder Equity
Net Receivables	+ 0.98	Non Current Assets Total

Short Term Investments	- 0.42	Retained Earnings
Common Stock Total Equity	- 0.34	Retained Earnings
Retained Earnings	- 0.34	Current Deferred Revenue
Common Stock Shares Outstanding	- 0.32	Retained Earnings
Cash And Short Term Investments	- 0.16	Retained Earnings
Other Stockholder Equity	- 0.13	Retained Earnings